Pfizer has completed its acquisition of Metsera, a clinical-stage biotech focused on obesity and cardiometabolic therapies, in a deal worth up to $7 billion (including milestone payments). The acquisition brings four of Metsera’s promising programs both injectable and oral under Pfizer’s umbrella, accelerating its push into the obesity market.
Glimpse:
Pfizer has taken full ownership of Metsera in a high-stakes acquisition, paying $65.60 per share plus potential milestone-based payouts to bring Metsera’s novel obesity and cardiometabolic pipeline into its portfolio. The deal, now closed at around $7 billion, strengthens Pfizer’s foothold in the booming weight-loss therapy sector with next-gen GLP-1 and amylin-based candidates.
Pfizer has completed its acquisition of Metsera, Inc., a clinical-stage biotech specializing in next-generation obesity and metabolic disease therapies. Under the terms, Metsera shareholders received $65.60 in cash per share, along with a contingent value right (CVR) for up to $20.65 per share, contingent on specific clinical and regulatory milestones.
The deal provides Pfizer access to four of Metsera’s promising therapeutic candidates: a weekly/monthly injectable GLP-1 receptor agonist (MET-097i), a monthly amylin analog (MET-233i), two oral GLP-1 receptor agonists set to begin trials soon, and preclinical nutrient-stimulated hormone therapies.Pfizer highlighted that these could offer differentiated efficacy, tolerability, and dosing advantages over existing obesity treatments.
According to Pfizer’s leadership, the acquisition aligns with its broader strategy to “direct investments to the most impactful opportunities.” Obesity is a major global health issue, linked to over 200 comorbidities and Pfizer believes Metsera’s pipeline can drive long-term impact.
Metsera’s co-founder and CEO, Whit Bernard, expressed optimism about the merger, noting that this move allows the company to scale its therapy development with Pfizer’s commercial, manufacturing, and regulatory muscle.
“We are excited to apply our deep cardiometabolic experience to accelerate a portfolio that includes potential best-in-class injectables, with clinical data differentiated by efficacy, tolerability and durability.”
By
HB Team
